openPR Logo

Press Releases from Invitek Biotechnology & Biodesign Ltd. (4 total)

Invitek concludes strategic alliance with Chinese partners

In November 2007 a master agreement between Invitek Biotechnology & Biodesign Ltd., Allrun Nano Science & Technology Co., Ltd. and Research Institute of Micro/Nano Science & Technology in Shanghai Jiao Tong University was signed at the 3rd International Nanotechnology Cooperation Symposium in Shanghai, China. Within this agreement the stragetic cooperation for development of new and innovative separation procedures of biomolecules (nucleic acids, proteins) and cells as well as of novel

Saliva test instead of blood test

New product – SaliGene® Collection Tube The SaliGene® Collection Tube is the easiest way to collect and preserve large amounts of DNA from saliva. It is easy-to-use and completely non-invasive, making it ideal for reliable self-administered collection. As part of the PSP® Spin Saliva DNA Kit SaliGene® features an all-in-one system for the collection, preservation, transportation and purification of DNA from saliva. Samples do not require special handling or storage because

New dimension in automation of nucleic acid purification and molecular diagnosti …

Invitek Biotechnolgy & Biodesign Ltd. announces the introduction of a new generation of superparamagnetic nanoparticles for nucleic acid isolation (InviMag® nano). In cooperation with the Chinese company Allrun Nano Science & Technology CO., Ltd. Invitek will adapt and extend its product portfolio for manual and fully automated magnetic extraction of nucleic acids during autumn 2007. The high-performance paramagnetic nanobeads with a controlled surface featuring various functionalities are applicable for efficient

Personalised medicine: milestone in the therapy control of humanised antibodies

CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for the therapy control of a new group of therapeutics, the so called humanised antibodies. Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which